LSE:GSKPharmaceuticals
GSK (LSE:GSK) Sees 6% Share Price Decline Over The Last Quarter
GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and the EMA's acceptance of an application for Nucala's expanded use. Despite these positive developments, the company's share price experienced a 6% decline over the last quarter. This movement occurred amid broader market volatility, where major indices faced notable declines, though recently improved following a pause on tariffs. GSK's earnings report revealed a decline...